DRAXIS Health Reports Fourth Quarter and Year E...(2007 2006 ...),Health

(unaudited)(unaudited) (unaudited)(unaudited)

REVENUES

$20,024 $23,106 Product sales $76,072 $83,545

433 465 Royalty and licensing 2,668 2,121

30 825 Anipryl(R) deferred revenues 120 3,301

-------------------------------------------------------------------------

$20,487 $24,396 $78,860 $88,967

-------------------------------------------------------------------------

-------------------------------------------------------------------------

$6,909 $10,446 Product Gross Margin $26,454 $36,462

34.5% 45.2% Product Gross Margin % 34.8% 43.6%

($1,171) $4,289 Operating income (loss) $2,148 $14,952

-5.7% 17.6% Operating Margin % 2.7% 16.8%

$24,796 $21,446 Cash and cash equivalents $24,796 $21,446

$0 $0 Total debt $0 $0

$2,395 $5,734 Cash flows from operating $12,551 $16,450

activities

(5,160) (2,251) Cash flows used in investing (13,394) (5,993)

activities

-------------------------------------------------------------------------

($2,765) $3,483 ($843) $10,457

-------------------------------------------------------------------------

-------------------------------------------------------------------------

($551) $3,687 Net income (loss) $1,658 $11,547

($0.01) $0.09 Basic and diluted earnings $0.04 $0.28

(loss) per share

Two
'/>"/>